MUC16 and ovarian cancer: Our data are consistent with Charkhchi et al., [4] who demonstrated that serum CA125 levels are high in 50% of early-stage tumors (mainly type I ovarian cancers) and 92% of advanced-stage tumors (mainly type II ovarian cancers).